Risk factors

Vicarious Surgical transitioned to the OTCID market tier after being suspended and delisted from the NYSE.

Cartesian Therapeutics faces clinical and commercial uncertainties regarding its lead mRNA product candidate Descartes-08 for autoimmune disease. The company addresses financial runway, tax loss carryforward limitations, and intellectual property enforcement risks.

Repay Holdings faces new risks around variable interest debt tied to SOFR, 2029 Notes conversion liabilities, and Tax Receivable Agreement acceleration triggers. Stock price volatility ranges shifted from a prior high of $11.05 down to $7.70 in the updated period.

Sharplink added 40 new risks, shifting its core business focus toward digital asset treasury management involving ETH and decentralized finance. The risk profile is now heavily dominated by cryptocurrency volatility, regulatory uncertainty regarding securities classification, and smart contract risks.

Septerna added critical disclosures regarding U.S. government shutdowns affecting the FDA and SEC, reliance on Chinese suppliers like WuXi, and potential patent infringement risks. The company noted specific exposures including hypoparathyroidism treatments and collaborations with Novo.

Spruce Biosciences faces substantial financial losses and relies heavily on ongoing clinical development of TA-ERT and tildacerfont.

The company faces heightened commercialization risks as neffy is its only approved product, relying heavily on global supply chains and collaboration partners. Regulatory scrutiny has intensified, notably with FDA untitled letters regarding TV advertisements and potential pricing pressures. Financial exposure includes a $100.0 million credit agreement and macroeconomic uncertainties impacting debt or equity financing.

The 2025 IPO placed $151.05 million into the Trust Account, generating $5.67 million of interest income and $5.31 million of net income.

Tiptree faces extensive new risks and uncertainty surrounding the pending sale of Fortegra for $1.65 billion in cash.

Personal loan marketplace performance and unsecured debt risks are newly highlighted for QuoteWizard.

Voyager Therapeutics faces new risks from government shutdowns disrupting FDA reviews, international tariff policies, and strict foreign anti-bribery and data privacy laws. Clinical programs like VY1706 and VY7523 remain in early development stages with historical collaboration terminations.

Zevra relies heavily on MIPLYFFA for 82% of revenue and faces intense pricing, manufacturing, and distribution risks.